PDS Biotechnology’s (PDSB) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report released on Thursday morning,Benzinga reports. They currently have a $21.00 price objective on the stock.

Separately, B. Riley decreased their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Stock Up 5.9 %

Shares of PDS Biotechnology stock opened at $1.26 on Thursday. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 52-week low of $1.13 and a 52-week high of $5.00. The company has a market capitalization of $48.12 million, a P/E ratio of -1.09 and a beta of 1.68. The company has a 50 day moving average of $1.45 and a 200 day moving average of $2.29.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after purchasing an additional 37,142 shares in the last quarter. Blair William & Co. IL raised its stake in PDS Biotechnology by 29.4% during the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after acquiring an additional 35,757 shares in the last quarter. Renaissance Technologies LLC raised its stake in PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after acquiring an additional 76,800 shares in the last quarter. XTX Topco Ltd lifted its position in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after acquiring an additional 47,528 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after acquiring an additional 48,132 shares in the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.